Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, p... by George, Daniel J, Spigel, David R, Gordan, Lucio N, Kochuparambil, Samith T, Molina, Ana M, Yorio, Jeff, Rezazadeh Kalebasty, Arash, McKean, Heidi, Tchekmedyian, Nishan, Tykodi, Scott S, Zhang, Joshua, Askelson, Margarita, Johansen, Jennifer L, Hutson, Thomas E

Get full text

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine by Goetz, Matthew P., McKean, Heidi A., Reid, Joel M., Mandrekar, Sumithra J., Tan, Angelina D., Kuffel, Mary A., Safgren, Stephanie L., McGovern, Renee M., Goldberg, Richard M., Grothey, Axel A., McWilliams, Robert, Erlichman, Charles, Ames, Matthew M.

Get full text

Quitting the smoke break: a successful partnership with the construction industry by Dupuis, Lorette, McKean, Heidi, Chow, Hilda

Get full text

Are Cancer Survivors/Patients Knowledgeable About Osteoporosis? Results from a Survey of 285 Chemotherapy-treated Cancer Patients and Their Companions by McKean, Heidi, MD, Looker, Sherry, RN, Hartmann, Lynn C., MD, Hayman, Suzanne R., MD, Kaur, Judith S., MD, McWilliams, Robert R., MD, Peethambaram, Prema P., MD, Stahl, Jean F., RN, Jatoi, Aminah, MD

Get full text

Abstract 5494: Cost analysis of genomic-directed therapy in patients with metastatic lung and colorectal cancers by Tutera, Seth, Olson, Marissa, Williams, Casey, Leyland-Jones, Brian, Huber, Mark, McKean, Heidi, Tolentino, Addison

Get full text

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy by Williams, Casey B, McMahon, Caitlin, Ali, Siraj M, Abramovitz, Mark, Williams, Kirstin A, Klein, Jessica, McKean, Heidi, Yelensky, Roman, George, Jr, Thomas J, Elvin, Julia A, Soman, Salil, Lipson, Doron, Chmielecki, Juliann, Morosini, Deborah, Miller, Vincent A, Stephens, Philip J, Ross, Jeffrey S, Leyland-Jones, Brian

Get full text

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy by Williams, Casey B, McMahon, Caitlin, Ali, Siraj M, Abramovitz, Mark, Williams, Kirstin A, Klein, Jessica, McKean, Heidi, Yelensky, Roman, George, Thomas J, Elvin, Julia A, Soman, Salil, Lipson, Doron, Chmielecki, Juliann, Morosini, Deborah, Miller, Vincent A, Stephens, Philip J, Ross, Jeffrey S, Leyland-Jones, Brian

Get full text

24899 Ixekizumab sustains high efficacy and a favorable safety profile in burdensome areas in patients with moderate-to-severe psoriasis: 5-year results from UNCOVER-2 by Papp, Kim, Blauvelt, Andrew, Puig, Luis, Elmaraghy, Hany, See, Kyoungah, McKean-Matthews, Missy, Crane, Heidi, Garrelts, Alyssa, Leonardi, Craig

Get full text

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced s... by Davar, Diwakar, Cavalcante, Ludimila, Lakhani, Nehal, Moser, Justin, Millward, Michael, McKean, Meredith, Voskoboynik, Mark, Sanborn, Rachel E, Grewal, Jaspreet S, Narayan, Ajita, Patnaik, Amita, Gainor, Justin F, Sznol, Mario, Enstrom, Amanda, Blanchfield, Lori, LeBlanc, Heidi, Thomas, Heather, Chisamore, Michael J, Peng, Stanford L, Naumovski, Allison

Get full text